Physician profile
Peter C Freebeck
NPI 1417931445
$1,595.01
in general payments reported to CMS, 2019-2025
16 companies · $13.66 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $390 · 2021: $32.84 · 2022: $76.33 · 2023: $116 · 2024: $49.14 · 2025: $13.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $179.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $327.03 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $262.44 | 2019-2023 | Airsupra |
| Genentech USA, INC. | $230.63 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.45 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $135.34 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $87.28 | 2019-2020 | |
| Ceribell, INC. | $49.14 | 2024 | Pocket Eeg Device |
| Merck Sharp & Dohme LLC | $47.00 | 2019-2020 | |
| Electromed, INC. | $46.76 | 2019 | |
| Philips North America LLC | $44.25 | 2019-2025 | Patient Interface Software |
| Vapotherm INC | $32.84 | 2021 | |
| Mylan Specialty L.P. | $27.23 | 2023 | Yupelri |
| Grifols USA, LLC | $24.38 | 2020 | |
| Csl Behring | $24.26 | 2020 | |
| Tactile Systems Technology INC | $22.12 | 2023 | Entre Plus, Flexitouch Plus |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Breathe Technologies, INC. | $18.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Freebeck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.